Literature DB >> 15867423

No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sézary syndrome.

Jeanette Lundin, Ben Kennedy, Claire Dearden, Martin J S Dyer, Anders Osterborg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15867423     DOI： 10.1182/blood-2004-11-4314

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  5 in total

1.  Alemtuzumab induced ST-segment elevation and acute myocardial dysfunction.

Authors:  Shirin Attarian; Cindy Y Wang; Jorge Romero; Stefan K Barta; Santiago Aparo; Mark A Menegus
Journal:  J Cardiol Cases       Date:  2014-07-28

2.  [Systemic treatment of cutaneous lymphomas].

Authors:  C-D Klemke
Journal:  Hautarzt       Date:  2011-06       Impact factor: 0.751

Review 3.  Beyond Anthracyclines: Preemptive Management of Cardiovascular Toxicity in the Era of Targeted Agents for Hematologic Malignancies.

Authors:  Tarsheen K Sethi; Basak Basdag; Nirmanmoh Bhatia; Javid Moslehi; Nishitha M Reddy
Journal:  Curr Hematol Malig Rep       Date:  2017-06       Impact factor: 3.952

Review 4.  Cardiac toxicity: old and new issues in anti-cancer drugs.

Authors:  M Sereno; A Brunello; A Chiappori; J Barriuso; E Casado; C Belda; J de Castro; J Feliu; M González-Barón
Journal:  Clin Transl Oncol       Date:  2008-01       Impact factor: 3.405

5.  Management of cutaneous T cell lymphoma: new and emerging targets and treatment options.

Authors:  Janet Y Li; Steven Horwitz; Alison Moskowitz; Patricia L Myskowski; Melissa Pulitzer; Christiane Querfeld
Journal:  Cancer Manag Res       Date:  2012-03-12       Impact factor: 3.989
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.